Cancer Treatment-Induced Cardiotoxicity: A Cardiac Stem Cell Disease?

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 8, Issue 1, 2010, Pages 55-75

  Prezioso, L ^a   Tanzi, S ^b   Galaverna, F ^a   Frati, C ^a   Testa, B ^a   Savi, M ^a,b   Graiani, G ^a   Lagrasta, C ^a,b   Cavalli, S ^a   Galati, S ^a   Madeddu, D ^a   Lodi Rizzini, E ^b   Ferraro, F ^b   Musso, E ^a,b   Stilli, D ^a,b   Urbanek, K ^f   Piegari, E ^d   De Angelis, A ^d   Maseri, A ^f   Rossi, F ^b   Quaini, E ^c,e   Quaini, F ^a   more..

^a UNIVERSITY OF PARMA   (Italy)

^b Department of Oncology ^*  (Italy)

^c Observatory of the Italian Society of Cardiac Surgery   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e Heart Care Foundation   (Italy)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anthracycline; Cancer treatment; Cardiac progenitors; Cardiotoxicity; Cardiovascular diseases; Regenerative medicine; Stem cells; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPECITABINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; GROWTH HORMONE; IMATINIB; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; BREAST CANCER; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL COMPARTMENTALIZATION; CELL POPULATION; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DERMATOFIBROSARCOMA PROTUBERANS; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; KIDNEY CARCINOMA; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; RISK FACTOR; STEM CELL; SYSTEMIC MASTOCYTOSIS;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIUM; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; STEM CELLS;

EID: 77950799118     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152510790796165     Document Type: Review

References (176)

1. Tilly, H.; Lepage, E.; Coiffier, B.; Blanc, M.; Herbrecht, R.; Bosly, A.; Attal, M.; Fillet, G.; Guettier, C.; Molina, T.J.; Gisselbrecht, C.; Reyes, F. Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 2003, 102, 4284.
2. Jones, S.E.; Savin, M.A.; Holmes, F.A. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol., 2006, 24, 5381.
3. Bonadonna, G.; Monfardini, S.; de Lena, M.; Fossati-Bellani, F. Clinical evaluation of adriamycin, a new antitumour antibiotic. Br. Med. J., 1969, 3, 503.
4. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Antrayclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56, 185.
5. Telli, M.L.; Hunt, S.A.; Carlson, R.W.; Guardino, A.E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol., 2007, 25, 3525.
6. Gianni, L.; Herman, E.H.; Lipshultz, S.E.; Minotti, G.; Sarvazyan, N.; Sawyer, D. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol., 2008, 26, 3777.
7. Quaini, F.; Cigola, E.; Lagrasta, C.; Saccani, G.; Quaini, E.; Rossi, C.; Olivetti, G.; Anversa, P. End-stage cardiac failure in humans is coupled with the induction of proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes. Circ. Res., 1994, 75, 1050.
8. Bergmann, O.; Bhardwaj, R.D.; Bernard, S.; Zdunek, S.; Barnabé-Heider, F.; Walsh, S.; Zupicich, J.; Alkass, K.; Buchholz, B.A.; Druid, H.; Jovinge, S.; Frisén J. Evidence for cardiomyocyte renewal in humans. Science, 2009, 324, 98.
9. Bearzi, C.; Rota, M.; Hosoda, T.; Tillmanns, J.; Nascimbene, A.; De Angelis, A.; Yasuzawa-Amano, S.; Trofimova, I.; Siggins, R.W.; Lecapitaine, N.; Cascapera, S.; Beltrami, A.P.; D'Alessan-dro, D.A.; Zias, E.; Quaini, F.; Urbanek, K.; Michler, R.E.; Bolli, R.; Kajstura, J.; Leri, A.; Anversa, P. Human cardiac stem cells. Proc. Natl. Acad. Sci. USA, 2007, 104, 14068.
10. Oh, H.; Bradfute, S.B.; Gallardo, T.D.; Nakamura, T.; Gaussin, V.; Mishina, Y.; Pocius, J.; Michael, L.H.; Behringer, R.R.; Garry, D.J.; Entman, M.L.; Schneider, M.D. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl. Acad. Sci. USA, 2003, 100, 12313.
11. Von Hoff, D.D.; Rozencweig, M.; Layard, M.; Slavik, M.; Muggia, F.M. Daunomicine induced cardiotoxicity in children and adults. A review of 110 cases. Am. J. Med., 1977, 62, 200.
12. Carrió, I.; Estorch, M.; Berná, L.; López-Pousa, J.; Tabernero, J.; Torres, G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J. Nucl. Med., 1995, 36, 2044.
13. Steinherz, L.J.; Steinherz, P.G.; Tan, C.T.; Heller, G.; Murphy, M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 1991, 266, 1672.
14. Pinder, M.C.; Duan, Z.; Goodwin, J.S.; Hortobagyi, G.N.; Giordano, S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol., 2007, 91, 37.
15. Jain, D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J. Nucl. Cardiol., 2000, 7, 53.
16. Lee, B.H.; Goodenday, L.S.; Muswick, G.J.; Yasnoff, W.A.; Leighton, R.F.; Skeel, R.T. Alterations in left ventricular diastolic function with doxorubicin therapy. J. Am. Coll. Cardiol., 1987, 9, 184.
17. Horenstein, M.S.; Vander Heide, R.S.; L'Ecuyer, T.J. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab., 2000, 71, 436.
18. Swain, S.M.; Whaley, F.S.; Ewer, M.S. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer, 2003, 97, 2869
19. Portera, C.C.; Swain, S.M. The heart of the matter. J. Clin. Oncol., 2007, 25, 3794.
20. Church, D.F.; Pryor, W.A. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect., 1985, 64, 111
21. Prescott, E.; Hippe, M.; Schnohr, P.; Hein, H.O.; Vestbo, J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. Br. Med. J., 1998, 316, 1043
22. Wilson, J.R.; Schwartz, J.S.; Sutton, M.S.; Ferraro, N.; Horowitz, L.N.; Reichek, N.; Josephson, M.E. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J. Am. Coll. Cardiol., 1983, 2, 403
23. Smith, W.M. Epidemiology of congestive heart failure. Am. J. Cardiol., 1985, 55, 3.
24. McKee, P.A.; Castelli, W.P.; McNamara, P.M.; Kannel, W.B. The natural history of congestive heart failure: the Framingham study. N. Engl. J. Med., 1971, 285, 1441.
25. Glader, E.L.; Stegmayr, B.; Norrving, B.; Terent, A.; Hulter-Asberg, K.; Wester, P.O.; Asplund, K. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke, 2003, 34, 1970.
26. Muss, H.B.; Woolf, S.H.; Cirrincione, C.; Weiss, R.B.; Budman, D.; Wood, W.C.; Henderson, I.C.; Hudis, C.; Winer, E.; Cohen, H.; Wheeler, J.; Norton, L. Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA, 2005, 293, 1073.
27. Doyle, J.J.; Neugut, A.I.; Jacobson, J.S.; Grann, V.R.; Hershman, D.L. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J. Clin. Oncol., 2005, 23, 8597.
28. Zambetti, M.; Moliterni, A.; Materazzo, C.; Stefanelli, M.; Cipriani, S.; Valagussa, P.; Bonadonna, G.; Gianni, L. Long term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J. Clin. Oncol., 2001, 19, 37.
29. Sawyer, D.B.; Zuppinger, C,; Miller, T.A.; Suter, T.M. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation, 2002, 105, 1551.
30. Ladas, E.J.; Jacobson, J.S.; Kennedy, D.D. Antioxidants and cancer therapy: a systematic review. J. Clin. Oncol., 2004, 22, 517.
31. Kalay, N.; Basar, E.; Ozdogru, I.; Er, O.; Cetinkaya, Y.; Dogan, A.; Inanc, T.; Oguzhan, A.; Eryol, N.K.; Topsakal, R.; Ergin, A. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol., 2006, 48, 2258.
32. Santos, D.L.; Moreno, A.J.; Leino, R.L.; Froberg, M.K.; Wallace, K.B. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol. Appl. Pharmacol., 2002, 185, 218.
33. Lipshultz, S.E.; Colan, S.D.; Gelber, R.D. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med., 1991, 324, 808.
34. Swain, S.M.; Whaley, F.S.; Gerber, M.C.; Weisberg, S.; York, M.; Spider, D.; Jones, S.E.; Wadler, S.; Desai, A.; Vogel, C.; Speyer, J.; Mittelman, A.; Reddy, S.; Pendergrass, K.; Velez-Garcia, E.; Ewer, M.S; Bianchine, J.R.; Gams, R.A. Cardioprotection with dexra-zoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol., 1997, 15, 1318.
35. Swain, S.M.; Vici, P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: export panel review. J. Cancer Res. Clin. Oncol., 2004, 130, 1.
36. Singal, P.K.; Iliskovic, N.; Li, T.; Kumar, D. Adriamycin cardio-myopathy: pathophysiology and prevention. FASEB J., 1997, 11, 931.
37. Urbanek, K.; Quaini, F.; Tasca, G.; Torella, D.; Castaldo, C.; Nadal-Ginard, B.; Leri, A.; Kajstura, J.; Quaini, E.; Anversa, P. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc. Natl. Acad. Sci. USA, 2003, 100, 10440.
38. Urbanek, K.; Torella, D.; Sheikh, F.; De Angelis, A.; Nurzynska, D.; Silvestri, F.; Beltrami, C.A.; Bussani, R.; Beltrami, A.P.; Quaini, F.; Bolli, R.; Leri, A.; Kajstura, J.; Anversa, P. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc. Natl. Acad. Sci. USA, 2005, 102, 8692.
39. Olivetti, G.; Abbi, R.; Quaini, F.; Kajstura, J.; Cheng, W.; Nitahara, J.A.; Quaini, E.; Di Loreto, C.; Beltrami, C.A.; Krajewsky, S.; Reed, J.; Anversa, P. Apoptosis in the failing human heart. N. Engl. J. Med., 1997, 336, 1131.
40. Kajstura, J.; Cheng, W.; Sarangarajan, R.; Li, P.; Li, B.; Nitahara, J.A.; Chapnick, S.; Reiss, K.; Olivetti, G.; Anversa, P. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am. J. Physiol., 1996, 271, H1215.
41. Guerra, S.; Leri, A.; Wang, X.; Finato, N.; Di Loreto, C.; Beltrami, C.A; Kajstura, J.; Anversa, P. Myocyte death in the failing human heart is gender dependent. Circ. Res., 1999, 85, 856.
42. Amir, G.; Ma, X.; Mohan Reddy, V.; Hanley, F.L.; Reinhartz, O.; Ramamoorthy, C.; Riemer, R.K. Dynamics of human myocardial progenitor cell populations in the neonatal period. Ann. Thorac. Surg, 2008, 86, 1311.
43. Tokarska-Schlattner, M.; Wallimann, T.; Schlattner, U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C. R. Biol., 2006, 329, 657.
44. Nicolay, K.; Fok J.J.; Voorhout, W.; Post, J.A.; de Kruijff, B. Cyto-fluorescence detection of adriamycin-mitochondria interactions in isolated, perfused rat heart. Biochim. Biophys. Acta, 1986, 887, 35.
45. Chen, B.; Peng, X.; Pentassuglia, L.; Lim, C.C.; Sawyer, D.B. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc. Toxicol., 2007, 7, 114.
46. Olson, R.D.; Mushlin, P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J., 1990, 4, 3076.
47. Singal, P.K.; Iliskovic, N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 1998, 339, 900.
48. Lipshultz, S.E.; Grenier, M.A.; Colan, S.D. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med., 1999, 340, 653; author reply, 655.
49. Menaschè, P. Cell-based Therapy for Heart Disease: A Clinically Oriented Perspective. Mol. Ther., 2009, 175, 758.
50. De Angelis, A.; Piegari, E.; Cappetta, D.; Marino, L.; Filippelli, A.; Berrino, L.; Ferreira-Martins, J.; Zheng, H.; Hosoda, T.; Rota, M.; Urbanek, K.; Kajstura, J.; Leri, A.; Rossi, F.; Anversa, P. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation, 2009, Dec 28. [Epub ahead of print].
51. Alvarez, J.; Scully, R.; Miller, T. Long-term effects of treatments for childhood cancers. Curr. Opin. Pediatr., 2007, 19, 23.
52. Oeffinger, K.C.; Mertens, A.C.; Sklar, C.A. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med., 2006, 355, 1572.
53. Kremer, L.C.; van Dalen, E.C.; Offringa, M. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J. Clin. Oncol., 2001, 19, 191.
54. Grenier, M.A.; Lipshultz, S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol., 1998, 25, 72
55. Kremer, L.C.; van der Pal, H.J.; Offringa, M. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol., 2002, 13, 819.
56. Barry, E.; Alvarez, J.A.; Scully, R.E. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin. Pharmacother., 2007, 8, 1039.
57. Krischer, J.P.; Epstein, S.; Cuthbertson, D.D.; Goorin, A.M.; Epstein, M.L.; Lipshultz, S.E. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J. Clin. Oncol., 1997, 15, 1544.
58. Simbre, V.C.; Duffy, S.A.; Dadlani, G.H.; Miller T.L.; Lipshultz S.E. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr. Drugs, 2005, 7, 187.
59. Pein, F.; Sakiroglu, O.; Dahan, M.; Lebidois, J.; Merlet, P.; Shamsaldin, A.; Villain, E.; de Vathaire, F.; Sidi, D.; Hartmann, O. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br. J. Cancer, 2004, 91, 37.
60. Lipshultz, S.E.; Lipsitz, S.R.; Mone, S.M. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N. Engl. J. Med., 1995, 332, 1738.
61. Lipshultz, S.E.; Lipsitz, S.R.; Sallan, S.E. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol., 2005, 23, 2629.
62. Lipshultz, S.E.; Alvarez, J.A.; Scully, R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer Heart, 2008, 94, 525.
63. Adams, M.J.; Lipshultz, S.E. Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr. Blood Cancer, 2005, 44, 600.
64. Lee, Y.T.; Chan, K.K.; Harris, P.A. Tissue disposition of doxorubi-cin in experimental animals. Med. Pediatr. Oncol., 1982, 10, 259.
65. Rodvold, K.A.; Rushing, D.A.; Tewksbury, D.A. Doxorubicin clearance in the obese. J. Clin. Oncol., 1988, 6, 1321.
66. Olivetti, G.; Giordano, G.; Corradi, D.; Melissari, M.; Lagrasta, C.; Gambert, S.R,; Anversa, P. J. Gender differences and aging: Effects on the human heart. Am. Coll. Cardiol., 1995, 26, 1068.
67. Leri, A.; Kajstura, J.; Li, B.; Sonnenblick, E.H.; Beltrami, C.A.; Anversa, P.; Frishman, W.H. Cardiomyocyte aging is gender-dependent: the local IGF-1-IGF-1R system. Heart Dis., 2000, 2, 108.
68. Anversa, P.; Palackal, T.; Sonnenblick, E.H.; Olivetti, G.; Meggs, L.G.; Capasso, J.M. Myocyte cell loss and myocyte cellular hyper-plasia in the hypertrophied aging rat heart. Circ. Res., 1990, 67, 871.
69. Pai, V.B.; Nahata, M.C. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Saf., 2000, 22, 263.
70. Ewer, M.S.; Lenihan, D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J. Clin. Oncol., 2008, 26, 1201.
71. Ritchie, J.L.; Bateman, T.M.; Bonow, R.O.; Crawford, M.H.; Gibbons, R.J.; Hall, R.J.; O'Rourke, R.A.; Parisi, A.F.; Verani, M.S. Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J. Am. Coll. Cardiol., 1995, 25, 521.
72. Jensen, B.V.; Skovsgaard, T.; Nielsen, S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective blinded long term observational study of outcome in 120 patients. Ann. Oncol., 2002, 13, 699.
73. Adamcova, M.; Simunek, T.; Kaiserova, H. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology, 2007, 237, 218.
74. Piegari, E.; Di Salvo, G.; Castaldi, B.; Vitelli, M.R.; Rodolico, G. Golino, P.; Calabrò, R.; Rossi, F.; Berrino, L. Myocardial strain analysis in a doxorubicin-induced cardiomyopathy model. Ultrasound Med. Biol., 2008, 34, 370.
75. Zuppinger, C.; Timolati, F.; Suter, T.M. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc. Toxicol., 2007, 7, 61.
76. Tassan-Mangina, S.; Codorean, D.; Metivier, M.; Costa, B.; Him-berlin, C.; Jouannaud, C.; Blaise, A.M.; Elaerts, J.; Nazeyrollas, P. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur. J. Echocardiogr., 2006, 7, 141.
77. Yu, C.M.; Sanderson, J.E.; Marwick, T.H.; Oh, J.K. Tissue doppler imaging a new prognosticator for cardiovascular diseases. J. Am. Coll. Cardiol., 2007, 49, 1903.
78. Lipshultz, S.E.; Sanders, S.P.; Goorin, A.M. Monitoring for anthracycline cardiotoxicity. Pediatrics, 1994, 93, 433.
79. Carver, J.R.; Schuster, S.J.; Glick, J.H. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities. J. Clin. Oncol., 2008, 26, 3122.
80. Cardinale, D.; Sandri, M.T.; Martinoni, A.; Borghini, E.; Civelli, M.; Lamantia, G.; Cinieri, S.; Martinelli, G.; Fiorentini, C.; Cipolla, C.M. Myocardial injury revealed by plasma troponin I in breast cancer treated with high dose chemotherapy. Ann. Oncol., 2002, 13, 710.
81. Meinardi, M.T.; van Veldhuisen, D.J.; Gietema, J.A.; Dolsma, W.V.; Boomsma, F.; van den Berg, M.P.; Volkers, C.; Haaksma, J.; de Vries, E.G.; Sleijfer, D.T.; van der Graaf, W.T. Prospective evaluation of early cardiac damage induced by epirubicin containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol., 2001, 19, 2764.
82. Ekstein, S.; Nir, A.; Rein, A.J.; Perles, Z.; Bar-Oz, B.; Salpeter, L.; Algur, N.; Weintraub, M. Weintraub M. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J. Pediatr. Hematol. Oncol., 2007, 29, 440.
83. Mavinkurve-Groothuis, A.M.; Groot-Loonen, J.; Bellersen, L.; Pourier, M.S.; Feuth, T.; Bökkerink, J.P.; Hoogerbrugge, P.M.; Kapusta, L. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr. Blood Cancer., 2009, 52, 631.
84. Lipshultz, S.E.; Giantris, A.L.; Lipsitz, S.R. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J. Clin. Oncol., 2002, 20, 1677.
85. Cardinale, D.; Colombo, A.; Sandri, M.T. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation, 2006, 114, 2474.
86. Nakamae, H.; Tsumura, K.; Terada, Y.; Nakane, T.; Nakamae, M.; Ohta, K.; Yamane, T.; Hino, M. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer, 2005, 104, 2492.
87. Lipshultz, S.E.; Colan, S.D. Cardiovascular trials in long-term survivors of childhood cancer. J. Clin. Oncol., 2004, 22, 769.
88. Lipshultz, S.E.; Lipsitz, S.R.; Sallan, S.E.; Simbre, V.C. 2nd.; Shaikh, S.L.; Mone, S.M.; Gelber, R.D.; Colan, S.D. Long-term enalapril therapy for left ventricular dysfunction in doxorubicintreated survivors of childhood cancer. J. Clin. Oncol., 2002, 20, 4517.
89. Carver, J.R.; Shapiro, C.L.; Ng, A.; Jacobs, L.; Schwartz, C.; Virgo, K.S.; Hagerty, K.L.; Somerfield, M.R.; Vaughn, D.J. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol., 2007, 25, 3991.
90. Silber, J.H.; Cnaan, A.; Clark, B.J.; Paridon, S.M.; Chin, A.J.; Rychik, J.; Hogarty, A.N.; Cohen, M.I.; Barber, G.; Rutkowski, M.; Kimball, T.R.; Delaat, C.; Steinherz, L.J.; Zhao, H. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol., 2004, 22, 820.
91. Lipshultz, S.E.; Rifai, N.; Dalton, V.M.; Levy, D.E.; Silverman, L.B.; Lipsitz, S.R.; Colan, S.D.; Asselin, B.L.; Barr, R.D.; Clavell, L.A.; Hurwitz, C.A.; Moghrabi, A.; Samson, Y.; Schorin, M.A.; Gelber, R.D.; Sallan, S.E. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med., 2004, 351, 145.
92. Menna, P.; Salvatorelli, E.; Minotti, G. Cardiotoxicity of antitumor drugs. Chem. Res. Toxicol., 2008, 21, 978.
93. Hershman, D.L.; Shao, T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology, (Williston Park), 2009, 23, 227.
94. Gabizon, A.A. Liposomal anthracyclines. Hematol. Oncol. Clin. North Am., 1994, 8, 431.
95. O'Brien, M.E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczak, P.; Ackland, S.P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol., 2004, 15, 440.
96. Santucci, L.; Mencarelli, A.; Renga, B.; Ceccobelli, D.; Pasut, G.; Veronese, F.M.; Distrutti, E.; Fiorucci, S. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anticancer Drugs., 2007, 18, 1081.
97. Kratz, F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trial. Expert Opin. Invest. Drugs, 2007, 16, 855.
98. Lipshultz, S.E.; Vlach, S.A.; Lipsitz, S.R. Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics, 2005, 115, 1613.
99. Houck, W.V.; Pan, L.C.; Kribbs, S.B.; Clair, M.J.; McDaniel, G.M.; Krombach, R.S.; Merritt, W.M.; Pirie, C.; Iannini, J.P.; Mukherjee, R.; Spinale, F.G. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with development of congestive heart failure. Circulation, 1999, 100, 2003.
100. Bruel, A.; Oxlund, H.; Nyengaard, J.R. Growth hormone increases the total number of myocyte nuclei in the left ventricle of adult rats. Growth Horm. IGF Res., 2002, 12, 106.
101. Bruel, A.; Oxlund, H.; Nyengaard, J.R. Growth hormone increases the total number of cardiac myocyte nuclei in young rats but not in old rats. Mech. Ageing Dev., 2002, 123, 1353.
102. Li, Q.; Wu, S.; Li, S.Y.; Lopez, F.L.; Du, M.; Kajstura, J.; Anversa, P.; Ren, J. Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H1398.
103. Urbanek, K.; Rota, M.; Cascapera, S.; Bearzi, C.; Nascimbene, A.; De Angelis, A.; Hosoda, T.; Chimenti, S.; Baker, M.; Limana, F.; Nurzynska, D.; Torella, D.; Rotatori, F.; Rastaldo, R.; Musso, E.; Quaini, F.; Leri, A.; Kajstura, J.; Anversa, P. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ. Res., 2005, 97, 663.
104. Erratum in: Circ. Res., 2006, 98, e27.
105. Iwasaki, M.; Adachi, Y.; Nishiue, T.; Minamino, K.; Suzuki, Y.; Zhang, Y.; Nakano, K.; Koike, Y.; Wang, J.; Mukaide, H.; Taketani, S.; Yuasa, F.; Tsubouchi, H.; Gohda, E.; Iwasaka, T.; Ikehara, S. Hepatocyte growth factor delivered by ultrasound-mediated destruction of microbubbles induces proliferation of cardiomyocytes and amelioration of left ventricular contractile function in doxorubicin-induced cardiomyopathy. Stem Cells, 2005, 23, 1589.
106. Carlo-Stella, C.; Di Nicola, M.; Milani, R.; Longoni, P.; Milanesi, M.; Bifulco, C.; Stucchi, C.; Guidetti, A.; Cleris, L.; Formelli, F.; Garotta, G.; Gianni, A.M. Age-and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recom-binant human growth hormone. Exp. Hematol., 2004, 32, 171.
107. Carlo-Stella, C.; Di Nicola, M.; Milani, R.; Guidetti, A.; Magni, M.; Milanesi, M.; Longoni, P.; Matteucci, P.; Formelli, F.; Ravagnani, F.; Corradini, P.; Gianni, A.M. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ Cells in Poor Mobilizers. Blood, 2004, 103, 3287.
108. Fazel, S.; Cimini, M.; Chen, L.; Li, S.; Angoulvant, D.; Fedak, P.; Verma, S.; Weisel, R.D.; Keating, A.; Li, R.K. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest., 006, 116, 1865.
109. Miller, T.L.; Horgan, S.; Lipshultz S.E. Exercise rehabilitation of pediatric patients with cardiovascular disease. Prog. Pediatr. Cardiol., 2005, 20, 27.
110. Werner, C.; Hanhoun, M.; Widmann, T.; Kazakov, A.; Semenov, A.; Pöss, J.; Bauersachs, J.; Thum, T.; Pfreundschuh, M.; Müller, P.; Haendeler, J.; Böhm, M.; Laufs, U. Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J. Am. Coll. Cardiol., 2008, 52, 470.
111. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235, 177.
112. Buzdar, A.U.; Ibrahim, N.K.; Francis, D.; Booser, D.J.; Thomas, E.S.; Theriault, R.L.; Pusztai, L.; Green, M.C.; Arun, B.K.; Giordano, S.H.; Cristofanilli, M.; Frye, D.K.; Smith, T.L.; Hunt, K.K.; Singletary, S.E.; Sahin, A.A.; Ewer, M.S.; Buchholz, T.A.; Berry, D.; Hortobagyi, G.N. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol., 2005, 16, 3676.
113. Buzdar, A.U.; Valero, V.; Ibrahim, N.K.; Francis, D.; Broglio, K.R.; Theriault, R.L.; Pusztai, L.; Green, M.C.; Singletary, S.E.; Hunt, K.K.; Sahin, A.A., Esteva, F.; Symmans, W.F.; Ewer, M.S.; Buchholz, T.A.; Hortobagyi, G.N. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res., 2007, 1, 228.
114. Gianni, L.; Eiermann, W.; Pusztai, L. Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC). J. Clin. Oncol., 2008, 26, 504.
115. Slamon, D.J.; Leyland-Jones, B.; Shak, S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 2001, 344, 783.
116. Cobleigh, M.A.; Vogel, C.L.; Tripathy, D. Multinational study of the efficacy and safety of humanised anti-HER2 cardiotoxicity associated with trastuzumab in MBC 181 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 1999, 17, 2639.
117. Vogel, C.; Cobleigh, M.; Tripathy, D. Efficacy and safety of trastu-zumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol., 2002, 20, 719.
118. Seidman, A.; Hudis, C.; Pierri, M.K.; Shak, S.; Paton, V.; Ashby, M.; Murphy, M.; Stewart, S.J.; Keefe, D. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol., 2002, 20, 1215.
119. Carter, P.; Presta, L.; Gorman, C.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 1992, 89, 4285.
120. Baselga, J.; Tripathy, D.; Mendelsohn, J. Phase II study of weakly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J. Clin. Oncol., 1996, 14, 737.
121. Pegram, M.D.; Lipton, A.; Hayes, D.F.; Weber, B.L.; Baselga, J.M.; Tripathy, D.; Baly, D.; Baughman, S.A.; Twaddell, T.; Glaspy, J.A.; Slamon, D.J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 1998, 16, 2659.
122. Shak, S. Herceptin Multinational Investigator Study Group overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin. Oncol., 1999, 26, 71.
123. Guarneri, V.; Lenihan, D..J.; Valero, V.; Durand, J.B.; Broglio, K.; Hess, K.R.; Michaud, L.B.; Gonzalez-Angulo, A.M.; Hortobagyi, G.N.; Esteva, F.J. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer center experience. J. Clin. Oncol., 2006, 24, 4107.
124. Tan-Chiu, E.; Yothers, G.; Romond, E.; Geyer, C.E., Jr.; Ewer, M.; Keefe, D.; Shannon, R.P.; Swain, S.M.; Brown, A.; Fehrenbacher, L.; Vogel, V.G.; Seay, T.E.; Rastogi, P.; Mamounas, E.P.; Wolmark, N.; Bryant, J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol., 2005, 23, 7811.
125. Suter, T.M.; Procter, M.; van Veldhuisen, D.J. Trastuzumab associated cardiac adverse effects in the Herceptin adjuvant trial. J. Clin. Oncol., 2007, 25, 3859.
126. Hunt, S.A.; Baker, D.W.; Chin, M.H.; Cinquegrani, M.P.; Feld-man, A.M.; Francis, G.S.; Ganiats, T.G.; Goldstein, S.; Gregoratos, G.; Jessup, M.L.; Noble, R.J.; Packer, M.; Silver, M.A.; Stevenson, L.W.; Gibbons, R.J.; Antman, E.M.; Alpert, J.S.; Faxon, D.P.; Fuster, V.; Gregoratos, G.; Jacobs, A.K.; Hiratzka, L.F.; Russell, R.O.; Smith, S.C., Jr. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation, endorsed by the Heart Failure Society of America. Circulation, 2001, 104, 2996.
127. Peng, X.; Chen, B.; Lim, C.C.; Sawyer. D.B. The Cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanisms into preventative medicine. Mol. Interv., 2005, 5, 163.
128. Gassmann, M.; Casagranda, F.; Orioli, D.; Simon, H.; Lai, C.; Klein, R.; Lemke, G. Aberrant neural and cardiac development in mice lacking the ERBB4 neuregulin receptor. Nature, 1995, 378, 390.
129. Meyer, D.; Birchmeier, C. Multiple essential functions of neuregulin in development. Nature, 1995, 378, 386.
130. Crone, S.A.; Zhao, Y.Y.; Fan, L.; Gu, Y.; Minamisawa, S.; Liu, Y.; Peterson, K.L.; Chen, J.; Kahn, R.; Condorelli, G.; Chien, K.R. Jr.; Lee, K.F. ERBB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med., 2002, 8, 459.
131. Ozcelik, C.; Erdmann, B.; Pilz, B.; Wettschureck, N.; Britsch, S.; Hübner, N.; Chien, K.R.; Birchmeier, C.; Garratt, A.N. Conditional mutation of the ErbB2 (Her2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA, 2002, 99, 8880.
132. Bersell, K.; Arab, S.; Haring, B.; Kuhn, B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell, 2009, 138, 257.
133. Ewer, M.S.; Lippman, S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol., 2005, 23, 2900.
134. Chien, K.R. Herceptin and the heart: a molecular modifier of cardiac failure. N. Engl. J. Med., 2006, 354, 789.
135. Jones, L.W.; Haykowsky, M.J.; Swartz, J.J. Early breast cancer therapy and cardiovascular injury. J. Am. Coll. Cardiol., 2007, 50, 435.
136. Force, T.; Krause, D.S.; Van Etten, R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer, 2007, 7, 332.
137. Motzer, R.J. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 115.
138. Demetri, G.D. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368, 1329.
139. Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Morgan, J.A.; Harris, D.M.; Ismail, N.S.; Chen, J.H.; Schoen, F.J.; Van den Abbeele, A.D.; Demetri, G.D.; Force, T.; Chen, M.H. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370, 2011.
140. Pfizer. Sutent (sunitinib) PrescribingInformation Available from: 〈http://www.pfizer.com-pfizer/download/uspi-sutent.pdf〉2007.
141. Schmidinger, M.; Zielinski, C.C.; Vogl, U.M.; Schmidinger, H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2008, 26, 5204.
142. Strevel, E.L.; Ing, D.J.; Siu, L.L. Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval. J. Clin. Oncol., 2007, 25, 3362.
143. Mego, M.; Reckova, M.; Obertova, J.; Sycova-Mila, Z.; Brozmanova, K.;
144. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Müller, M.; Druker, B.J.; Lydon, N. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56, 100.
145. Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; Fanning, S.; Zimmerman, J.; Lydon, N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 1996, 2, 561.
146. Okuda, K.; Weisberg, E.; Gilliland, D.G.; Griffin, J.D. ARG tyrosine kinase activity is inhibited by STI571. Blood, 2001, 97, 2440.
147. Kerkela, R.; Grazette, L.; Yacobi, R.; Iliescu, C.; Patten, R.; Beahm, C.; Walters, B.; Shevtsov, S.; Pesant, S.; Clubb, F.J.; Rosenzweig, A.; Salomon, R.N.; Van Etten, R.A.; Alroy, J.; Durand, J.B.; Force, T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med, 2006, 12, 908.
148. Ribeiro, A.L,; Marcolino, M.S.; Bittencourt, H.N.S.; Barbosa, M.M.; Nunes Mdo, C.; Xavier, V.F.; Clementino, N.C. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk. Res., 2008, 32, 1809.
149. Force, T. In reply to "cardiotoxicity of the cancer therapeutic agent imatinib mesylate". Nat. Med., 2007, 13, 15.
150. Urano, F.; Wang, X.; Bertolotti, A.; Zhang, Y.; Chung, P.; Harding, H.P.; Ron, D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science, 2000, 287, 664.
151. Tsuruta, F.; Sunayama, J.; Mori, Y.; Hattori, S.; Shimizu, S.; Tsujimoto, Y.; Yoshioka, K.; Masuyama, N.; Gotoh, Y. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J., 2004, 23, 1889.
152. Beltrami, A.P.; Barlucchi, L.; Torella, D.; Baker, M.; Limana, F.; Cimenti, S.; Kasahara, H.; Rota, M.; Musso, E.; Urbanek, K.; Leri, A.; Kajstura, J.; Nadal-Ginard, B.; Anversa, P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 2003, 114, 763.
153. Chabot, B.; Stephenson, D.A.; Chapman, V.M.; Besmer, P.; Bernstein, A. The proto-oncogene c-kit encoding a transmembrane tyro-sine kinase receptor maps to the mouse W locus. Nature, 1988, 335, 88.
154. Bernex, F.; De Sepulveda, P.; Kress, C.; Elbaz, C.; Delouis, C. Spatial and temporal patterns of c-kit expressing cells in WlacZ/+and WlacZ/ WlacZ mouse embryos. Development, 1996, 122, 3023.
155. Waskow, C.; Paul, S.; Haller, C.; Gassmann, M.; Rodewald, H. Viable c-kit (W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity, 2002, 17, 277.
156. Cable, J.; Jackson, I.J.; Steel, K.P. Mutations at the W locus affects survival of neural crest-derived melanocytes in the mouse. Mech. Dev., 1995, 50, 139.
157. Schmelzle, T.; Hall, M.N. TOR, a central controller of cell growth. Cell, 2000, 103, 253.
158. Blume-Jensen, P.; Jiang, G.; Hyman, R.; Lee, K.F.; O'Gorman, S.; Hunter, T. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility. Nat. Genet., 2000, 24, 157.
159. Cramer, K.; Nieborowska-Skorska, M.; Koptyra, M.; Slupianek, A.; Penserga, E.T.; Eaves, CJ.; Aulitzky, W.; Skorski, T. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, and unfaithful DNA double strand break repair. Cancer Res., 2008, 68, 6884.
160. Suter, T.M.; Cook-Bruns, N.; Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast, 2004, 13, 173.
161. Chia, S.; Clemons, M.; Martin, L.A.; Rodgers, A.; Gelmon, K.; Pond, G.R.; Panasci, L. Pegylated liposomal doxorubicin and tras-tuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J. Clin. Oncol., 2006, 24, 2773.
162. Untch, M.; Eidtmann, H.; du Bois, A.; Meerpohl, H.G.; Thomssen, C.; Ebert, A.; Harbeck, N.; Jackisch, C.; Heilman, V.; Emons, G.; Wallwiener, D.; Wiese, W.; Blohmer, J.U.; Hoffken, K.; Kuhn, W.; Reichardt, P.; Muscholl, M.; Pauschinger, M.; Langer, B.; Lück, H.J. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: Results of a phase I trial. Eur. J. Cancer, 2004, 40, 988.
163. Joensuu, H.; Kellokumpu-Lehtinen, P.L.; Bono, P.; Alanko, T.; Kataja, V.; Asola, R.; Utriainen, T.; Kokko, R.; Hemminki, A.; Tarkkanen, M.; Turpeenniemi-Hujanen, T.; Jyrkkiö, S.; Flander, M.; Helle, L.; Ingalsuo, S.; Johansson, K.; Jääskeläinen, AS.; Pajunen, M.; Rauhala, M.; Kaleva-Kerola, J.; Salminen, T.; Leinonen, M.; Elomaa, I.; Isola, J. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med., 2006, 354, 809.
164. Van Royen, N.; Jaffe, C.C.; Krumholz, H.M.; Johnson, K.M.; Lynch, P.J.; Natale, D.; Atkinson, P.; Deman, P.; Wackers, F.J. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am. J. Cardiol., 1996, 77, 843.
165. Bellenger, N.G.; Burgess, M.I.; Ray, S.G.; Lahiri, A.; Coats, A.J.; Cleland, J.G.; Pennell, D.J. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance: Are they interchangeable? Eur. Heart J., 2000, 21, 1387.
166. Godkar, D.; Bachu, K.; Dave, B.; Megna, R.; Niranjan, S.; Khanna, A. Comparison and co-relation of invasive and non-invasive methods of ejection fraction measurement. J. Natl. Med. Assoc., 2007, 99, 1227.
167. Mackey, J.R.; Clemons, M.; Côté, M.A.; Delgado, D.; Dent, S.; Paterson, A.; Provencher, L.; Sawyer, B.; Verma, S. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr. Oncol., 2008, 15, 24.
168. Khakoo, A.Y.; Kassiotis, C.M.; Tannir, N.; Plana, J.C.; Halushka, M.; Bickford, C.; Trent, J. 2nd.; Champion, J.C.; Durand, J.B.; Lenihan, D.J. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer, 2008, 112, 2500.
169. Joensuu, H. Cardiac toxicity of sunitinib. Lancet, 2007, 370, 1978.
170. Ewer, M.S.; O'Shaughnessy, J.A. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin. Breast Cancer, 2007, 7, 600.
171. Hunt, S.A.; Abraham, W.T.; Chin, M.H. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation, 2005, 112, e154.
172. Izumiya, Y.; Shiojima, I.; Sato, K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension, 2006, 47, 887.
173. Oliveira, P.J.; Goncalves, L.; Monteiro, P.; Providencia, L.A.; Moreno, A.J. Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? Curr. Vasc. Pharmacol., 2005, 3, 147.
174. Carreira, R.S.; Monteiro, P.; Gon Alves, L.M.; Providência, L.A. Carvedilol: just another beta-blocker or a powerful cardioprotector? Cardiovasc. Hematol. Disord. Drug Targets, 2006, 6, 257.
175. Jones, S.P.; Teshima, Y.; Akao, M. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ. Res., 2003, 93, 697.
176. Fernandez, A.; Sanguino, A.; Peng, Z.; Ozturk, E.; Chen, J.; Crespo, A.; Wulf, S.; Shavrin, A.; Qin, C.; Ma, J.; Trent, J.; Lin, Y.; Han, HD.; Mangala, LS. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J. Clin. Invest., 2007, 117, 3650.